AU2008219269B2 - Combination therapy using TNF and alfa-galactosyl ceramide - Google Patents

Combination therapy using TNF and alfa-galactosyl ceramide Download PDF

Info

Publication number
AU2008219269B2
AU2008219269B2 AU2008219269A AU2008219269A AU2008219269B2 AU 2008219269 B2 AU2008219269 B2 AU 2008219269B2 AU 2008219269 A AU2008219269 A AU 2008219269A AU 2008219269 A AU2008219269 A AU 2008219269A AU 2008219269 B2 AU2008219269 B2 AU 2008219269B2
Authority
AU
Australia
Prior art keywords
tnf
alfa
galcer
treatment
tumour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2008219269A
Other languages
English (en)
Other versions
AU2008219269A1 (en
Inventor
Peter Brouckaert
Dirk Elewaut
Leander Huyghe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Universiteit Gent
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Vlaams Instituut voor Biotechnologie VIB filed Critical Universiteit Gent
Publication of AU2008219269A1 publication Critical patent/AU2008219269A1/en
Application granted granted Critical
Publication of AU2008219269B2 publication Critical patent/AU2008219269B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008219269A 2007-02-21 2008-02-20 Combination therapy using TNF and alfa-galactosyl ceramide Expired - Fee Related AU2008219269B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07102787 2007-02-21
EP07102787.4 2007-02-21
PCT/EP2008/052055 WO2008101951A1 (en) 2007-02-21 2008-02-20 Combination therapy using tnf and alfa-galactosyl ceramide

Publications (2)

Publication Number Publication Date
AU2008219269A1 AU2008219269A1 (en) 2008-08-28
AU2008219269B2 true AU2008219269B2 (en) 2012-10-25

Family

ID=39495301

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008219269A Expired - Fee Related AU2008219269B2 (en) 2007-02-21 2008-02-20 Combination therapy using TNF and alfa-galactosyl ceramide

Country Status (6)

Country Link
US (1) US7959907B2 (OSRAM)
EP (1) EP2117583B1 (OSRAM)
JP (1) JP2010519274A (OSRAM)
AU (1) AU2008219269B2 (OSRAM)
CA (1) CA2678088A1 (OSRAM)
WO (1) WO2008101951A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008219269B2 (en) 2007-02-21 2012-10-25 Universiteit Gent Combination therapy using TNF and alfa-galactosyl ceramide
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4677064A (en) 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US6001619A (en) 1995-10-04 1999-12-14 Cold Spring Harbor Laboratory Ubiquitin ligases, and uses related thereto
AU782355B2 (en) 1999-06-11 2005-07-21 Hsc Research And Development Limited Partnership Antagonists of BMP and TGFbeta signalling pathways
US7273852B2 (en) 2002-06-13 2007-09-25 The Research Foundation Of The City University Of New York Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
WO2005003167A1 (en) 2003-07-01 2005-01-13 Vib Vzw Ubiquitinated tnf receptor 2 and its uses
WO2006026389A2 (en) 2004-08-27 2006-03-09 Albert Einstein College Of Medicine Of Yeshiva University Ceramide derivatives as modulators of immunity and autoimmunity
AU2008219269B2 (en) 2007-02-21 2012-10-25 Universiteit Gent Combination therapy using TNF and alfa-galactosyl ceramide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAKUI ET AL, CLINICAL & EXPERIMENTAL METASTASIS, VOL 18, 2000, PAGES 147-153 *

Also Published As

Publication number Publication date
AU2008219269A1 (en) 2008-08-28
JP2010519274A (ja) 2010-06-03
US20100166697A1 (en) 2010-07-01
WO2008101951A1 (en) 2008-08-28
EP2117583A1 (en) 2009-11-18
EP2117583B1 (en) 2013-05-22
CA2678088A1 (en) 2008-08-28
US7959907B2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
Garay et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help
Cameron et al. Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.
Lasek et al. Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice
EP3344256B1 (en) Compositions for the treatment of joints
Nakata et al. Augmented antitumor effect of recombinant human interleukin-1α by indomethacin
AU2008219269B2 (en) Combination therapy using TNF and alfa-galactosyl ceramide
Sarkar et al. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
AU2012340446B2 (en) Apoaequorin for reducing neuronal injury due to ischemia
Negrier et al. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer
Santini et al. Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Ohno Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
WO2016012608A1 (en) Compositions comprising granulocyte-macrophage colony-stimulating factor for the treatment of inflammatory bowel disease
Kuzmits et al. Phase II results with recombinant interferons: renal cell carcinoma and malignant melanoma
Balemans et al. PEG‐IL‐2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclopphosphamide
CA2520400A1 (en) Treatment of aspergillus infections with thymosin alpha 1
Golab et al. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo.
Frankfurt et al. Growth factors in leukemia
ES3009748T3 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
Gottlieb Cytokine manipulation of the immune response in the treatment of human acute leukaemia
Lasek et al. Augmentation of antitumor efficacy by the combination of actinomycin D with tumor necrosis factor-alpha and interferon-gamma on a melanoma model in mice
IJzermans et al. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach
Ganser Hematopoietic growth factors in the treatment of the myelodysplastic syndromes
TW202019440A (zh) 用於治療癌症之組合療法
Chudgar et al. Recombinant human interleukin-1 receptor antagonist protects early myeloid progenitors in a murine model of cyclophosphamide-induced myelotoxicity

Legal Events

Date Code Title Description
MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee